Home > PJ (current issue) > Products | Search

PJ Online homeThe Pharmaceutical Journal
Vol 275 No 7375 p603
12 November 2005

This article
Reprint   Photocopy

PDF 50K, Acrobat Reader


Products

    Prescription Products SPC changes

Prescription Products

Crestor 5mg
Crestor (rosuvastatin) tablets 5mg are now available from AstraZeneca. The summary of product characteristics for Crestor has been updated. It now states that 5mg is the recommended starting dose in patients of Asian ancestry and for patients with moderate renal impairment or predisposing factors for myopathy (including renal impairment, hypothyroidism, hereditary muscular disorders, alcohol abuse, age over 70 years, risk of an increase in plasma levels and concomitant use of fibrates.) Net price, 28, £18.03. Legal category: POM. See SPC.

Sertraline
Sertraline tablets 50mg and 100mg are now available from PLIVA and Sandoz. Net price 50mg, 28, £17.50 (PLIVA) and £17.82 (Sandoz), 100mg, 28, £28.50 (PLIVA) and £29.16 (Sandoz). Legal category: POM.

Zamadol 24hr
Zamadol 24hr (tramadol) prolonged release tablets
150mg, 200mg, 300mg and
400mg are now available from Viatris. Net price, 28, 150mg £10.70, 200mg £14.26, 300mg £21.39, 400mg £28.51. Legal category: POM.

Back to Top


SPC changes

Enbrel
The summary of product characteristics for Enbrel (etanercept; Wyeth) now states that Enbrel is not recommended for the treatment of Wegener’s granulomatosis. See SPC.

Meningitec
The summary of product characteristics for Meningitec (meningococcal group C conjugate vaccine; Wyeth) now includes information on a two-dose primary schedule, booster dose and concomitant use of investigation pneumococcal conjugate vaccine. The SPC states that for infants up to the age of 12 months, two doses should be given (each of 0.5ml). The first dose should not be given earlier than two months of age and there should be an interval of at least two months between doses. The SPC also now recommends that a booster dose be given after completion of the primary immunisation series in infants.
See SPC.

Back to Top

©The Pharmaceutical Journal